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Crystal Structure of a Truncated Epidermal
Growth Factor Receptor Extracellular Domain
Bound to Transforming Growth Factor 
heterodimers and possibly higher-order oligomers, fol-
lowing activation by a subset of a dozen potential li-
gands including EGF, transforming growth factor 
(TGF), amphiregulin, betacellulin, epiregulin, heparin
binding EGF, epigen, and the neuregulins, giving rise to
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343 Royal Parade cellular cytoplasmic tyrosine kinase that is flanked by
noncatalytic regulatory regions (Ullrich et al., 1984). TheParkville, Victoria 3052
Australia extracellular portion of human EGFR (residues 1–621)
consists of four subdomains, L1, CR1, L2, and CR2 (Bajaj
et al., 1987; Ward et al., 1995), also referred to as do-
mains I–IV (Lax et al., 1988).Summary
Ligand-induced receptor dimers have been proposed
as the primary signaling system for EGFR (Lemmon andWe report the crystal structure, at 2.5 A˚ resolution, of
a truncated human EGFR ectodomain bound to TGF. Schlessinger, 1994; Moriki et al., 2001) with the stoichi-
ometry of the EGFR dimer complex being 2:2 (LemmonTGF interacts with both L1 and L2 domains of EGFR,
making many main chain contacts with L1 and inter- et al., 1997). Two models for the nature of the 2:2 dimer
were described which could not be distinguished. Theacting with L2 via key conserved residues. The results
indicate how EGFR family members can bind a family favored model was ligand-mediated dimerization, where
each EGF molecule made contact with both sEGFR mol-of highly variable ligands. In the 2:2 TGF:sEGFR501
complex, each ligand interacts with only one receptor ecules. The alternative was receptor-mediated dimer-
ization, where each ligand binds to only one sEGFRmolecule. There are two types of dimers in the asym-
metric unit: a head-to-head dimer involving contacts molecule, inducing a conformational change that pro-
motes receptor-receptor contacts (Lemmon et al.,between the L1 and L2 domains and a back-to-back
dimer dominated by interactions between the CR1 do- 1997).
Recently we described a truncated, soluble versionmains of each receptor. Based on sequence conserva-
tion, buried surface area, and mutagenesis experi- of the hEGFR extracellular domain, comprising residues
1–501 (sEGFR501), which binds human EGF or TGFments, the back-to-back dimer is favored to be
biologically relevant. with 13- to 14-fold higher affinity than the full-length
EGFR ectodomain and is capable of forming 2:2 dimers
in the presence of EGF (Elleman et al., 2001). In thisIntroduction
report we describe the use of sEGFR501 to generate
crystals of the human TGF:sEGFR501 dimer complexThe biology and biochemistry of the epidermal growth
factor receptor (EGFR) system has intrigued scientists and determine the three-dimensional structure to 2.5 A˚
resolution. Previous reports on crystallization of anand clinicians for more than twenty-five years. Aberrant
signaling by the EGF/EGFR family is associated with EGF:EGFR complex have used the EGFR ectodomain
secreted from A431 tumor cells. This soluble receptora number of cancers including brain, head and neck,
pancreatic, and colorectal tumors, making it a significant consists of residues 1–615 fused to an additional 18
amino acids (Ullrich et al., 1984) and gave crystals thattherapeutic target (reviewed in Yarden, 2001). Further-
more, a constitutively active mutant form of the receptor, diffracted to 10 A˚ (Gunther et al., 1990), 6 A˚ (Weber et
al., 1994), or 4.5 A˚ (Degenhardt et al., 1998).in which exons 2–7 (coding for residues 6–273) are de-
leted, has been observed in many glioblastoma, breast,
and ovarian cancers (Moscatello et al., 1995). Results and Discussion
Four members of the EGFR family of tyrosine kinases
have been identified in vertebrates, namely EGFR Overall Structure
(HER1/ErbB1), ErbB2 (Neu/HER2), ErbB3 (HER3), and sEGFR501 is comprised of three structural domains,
ErbB4 (HER4). They are capable of forming homo- or namely L1, CR1, and L2, plus the first module from the
second Cys-rich region CR2. Crystals of TGF:sEGFR501
contain two molecules of each polypeptide in the asym-5 Correspondence: tgarrett@wehi.edu.au (T.P.J.G.), tony.burgess@
ludwig.edu.au (A.W.B.), colin.ward@hsn.csiro.au (C.W.W.) metric unit. Crystallographic statistics are given in Table
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Table 1. Summary of Crystallographic Data
Completeness (%) Number Phasing
Data Set Resolution (A˚) Mean I/s Rmergea (Multiplicity) of Sites Rcullisb Powerc f.o.m.d
Native 2.9 11.1 0.129 96.9 (2.78) 0.31/0.84
Pt(NO3)2 2.8 11.9 0.095 97.8 (3.85) 4 0.71 0.71
PIP 2.5 10.8 0.075 90.2 (3.17) 2 0.91 0.91
K2Au(CN)2 3.0 9.1 0.091 97.8 (3.43) 4 0.21 2.21
Refinement Number of Reflections Number
Resolution (A˚) (Free) of Atoms Rcryste Rfreee Bondsf (A˚) Anglesf ()
20–2.5 48,006 (2379) 8,687 0.237 0.289 0.007 1.50
PIP, di--iodobis(ethylenediamine)diplatinum nitrate
a Rmerge  hj |Ihj  Ih|/hj Ih, where Ihj is an intensity measurement j of Ih and Ih is the mean of a reflection h.
b Rcullis  h||FPH  FP|  |FHcalc||/h||FPH|  |FP||, where FPH, FP, and FHcalc are, respectively, derivative, native, and heavy atom structure factors
for centric reflection h.
c Phasing power  h|FHcalc|/h, where FHcalc is defined above and  is the lack of closure.
d f.o.m. (figure of merit)  cos(	h)
, where 	h is the error in the phase angle for reflection h. Values are given before and after density
modification.
e Rcryst and Rfree are defined in the CNS manual (Brunger et al., 1998).
f Rms deviation for bond distances and angles.
1. There are two possible dimer interactions: a back-to- sEGFR501 molecule and makes contact with only one
receptor molecule in the dimer. In the back-to-back di-back dimer dominated by interactions between the CR1
domains of each receptor (Figures 1A and 1B, see Sup- mer, the two ligands are located on opposite sides of
the complex with the closest approach 70.9 A˚ apartplemental Figures S1 and S2 at http://www.cell.com/
cgi/content/full/110/6/763/DC1) and a head-to-head di- (Figure 1A). In the head-to-head dimer, the two ligands
are centrally located and are separated by 15 A˚ (Fig-mer involving contacts between the L1 and L2 domains
(Figures 1C and 1D). The back-to-back complex is ap- ure 1D).
We conclude that the back-to-back dimer corre-proximately 33  78  103 A˚ while the head-to-head
complex is 65  75  128 A˚. Each TGF molecule is sponds to the 2:2 TGF:sEGFR501 complex that is
formed in solution (Elleman et al., 2001) from compari-clamped between the L1 and L2 domains from the same
Figure 1. Polypeptide Trace for the 2:2 TGF:sEGFR501 Complex
(A) Side view of the back-to-back dimer. The sEGFR501 molecules are shown in orange (molecule A) and magenta (molecule B). The two
TGF molecules are colored green and lilac. Disulfide bonds are drawn in yellow.
(B) The back-to-back dimer viewed down the dimer axis.
(C) Side view of the head-to-head dimer.
(D) The head-to-head dimer viewed down the dimer axis.
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sons of the amount of buried surface area in the two
dimer options, the lack of symmetry in the head-to-head
dimer compared to that seen in the back-to-back dimer,
the sequence conservation at the dimer interfaces (de-
scribed later), and the characteristics of the receptors
mutated at both interfaces (described later). In the head-
to-head dimer, only 510 A˚2 of accessible surface area
is buried on each molecule, and this is distributed over
two patches 39 A˚ apart. The residues involved are 21,
24, 25, 28, and 48–51 on both L1s, 471, 473, 474, 476,
and 477 on both L2s, plus 32 (molecule A) and 443 and
478 from molecule B. In contrast, in the back-to-back
dimer, 1125 A˚2 on each receptor is buried (see later for
details). Biologically relevant protein-protein interfaces
usually bury more than 700 A˚2 of surface per molecule
and often about 1000 A˚2 (Lo Conte et al., 1999), implying
that the back-to-back configuration is more likely to be
the functional dimer. There is a lack of symmetry at the
two L1-L2 interfaces in the head-to-head dimer that
corresponds to a 6 A˚ translation of the L2 helix (residues Figure 2. Comparison of sEGFR501 with the First Three Domains
471–479) relative to L1 (Figure 1D). Such structural ambi- of IGF-1R
guity is not seen in the back-to-back dimer, the noncrys- For clarity the ligand in the TGF:sEGFR501 complex is not shown.
tallographic symmetry being very close to a pure 2-fold L1 domains are oriented similarly. Helices are indicated by curled,
red ribbons and  strands by broad arrows. The blue, green, androtation, implying that this is the functional dimer. It is
yellow  strands depict the three prominent parallel  sheets withinfurther supported by experiments where a model of the
the L1 and L2 domains. The  strands in the Cys-rich domains areEGF receptor CR2 domain (Jorissen et al., 2000) was
colored orange, except for those in the CR1 loop, which are colored
superimposed onto the structure determined here for brown. The black strand forms part of a  sheet with the ligand.
the first modules of the CR2 domains of the two The side chains of disulfide-linked cysteine residues are depicted
sEGFR501 molecules. In the back-to-back dimer, the as yellow sticks.
rod-like domains of CR2 project toward each other un-
derneath sEGFR501, consistent with the ability to form
disulfide-linked dimers via a Cys mutation three residues For both L1 and L2 domains of EGFR, the long 
upstream of the transmembrane domain when ligand strand in the first turn of the solenoid is missing. In L1
binds to mutant receptors (Sorokin et al., 1994). The it is replaced by a long V-shaped excursion (residues
same superimposition performed on the head-to-head 8–18) that sits over the large  sheet of L1 to form a
dimer results in the modeled CR2 domains projecting major part of L1’s ligand binding surface (Figure 2). In
away from each other and is inconsistent with the Cys L2 it is replaced by a loop (residues 316–326) that also
mutant data (Sorokin et al., 1994). Finally, the back-to- contacts the ligand (see Ligand-Receptor Interactions).
back dimer has now been seen in another crystal form These two loops correspond to major insertions in the
of the EGFR complex (Ogiso et al., 2002 [this issue of first turn of each of the L1 and L2 domains of EGFR
Cell]). relative to IGF-1R (Figure 3A). A third insertion is seen as
an extra loop in the second turn of L2 (residues 351–369),
which corresponds to the epitope for LA22, LA58, andReceptor Domain Architecture
The L1, CR1, and L2 domains of EGFR show both struc- LA90, antibodies that prevent ligand binding (Wu et al.,
1989). These three loops, together with conserved loopstural (Figure 2) and sequence (Figure 3) homology to the
first three domains of the type I insulin-like growth factor in the fourth turn of the solenoid, all participate in impor-
tant interactions with the ligand.receptor (Garrett et al., 1998), with the L domains resem-
bling other leucine-rich repeat or solenoid proteins The arrangement of the eight disulfide-bonded mod-
ules in CR1 is similar to that of IGF-1R (Figures 3A and(Ward and Garrett, 2001; Kobe and Kajava, 2001). Like
the IGF-1R, the EGFR L domains (1) comprise six turns 3B), although the slightly different orientations result in
CR1 of the EGFR being a straight rod, bent at moduleof a  helix capped at each end by a helix and a disulfide
bond; (2) have a conserved Trp (Trp176 in CR1 and 6, compared to the curved CR domain of IGF-1R (Figure
2). The CR1 domain of EGFR makes contact with L1Trp492 in CR2) inserted between the fourth and fifth
turns of the  helix; (3) contain a large  sheet (second along one side of the solenoid (sheet 1, burying 1375 A˚2
of accessible surface area) and also makes appreciablesheet, green in Figure 2) flanked by two shorter ones
on either side (blue and yellow) with the face opposite contact with the L2 domain via modules 6 and 7 (burying
860 A˚2 ). This is different from the IGF-1R structure,the large  sheet being more irregular; (4) have a stack
of conserved Gly residues at positions 39, 63, 85, and where the L2 domain is rotated away to lie almost per-
pendicular to the axis of L1 (Figure 2). Thus, the C-ter-122 in L1 and 343, 379, 404, and 435 in L2 (Figure 3A)
at the edge before the second  sheet and a short Asn minal region of CR1 may act as a hinge in the ligand-free
form of the EGFR as modules 7 and 8 appear somewhatladder at the edge after it; and (5) have a loop from the
fourth turn of each solenoid that protrudes from the mobile, having some of the largest temperature factors
in the structure.large (second)  sheet.
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Figure 3. Structure-Based Sequence Alignment of the Human EGFR Ectodomain, Human TGF, and Related Proteins
(A) The receptor L1 and L2 domains plus the first module of the Cys-rich regions, CR1 and CR2. Positions with conserved physicochemical
properties of amino acids are boxed. Disulfide bond connections are shown as solid lines. Secondary structure elements are indicated above
and below the sequences as cylinders for  helices and arrows for  strands (color-coding is the same as Figure 2). Residues buried at
different protein-protein interfaces are indicated by: T at the TGF, L1, and L2 interfaces; R at the L1-L2 contacts; and P at the CR1 loop
interface.
(B) Modules 2–8 of the receptor Cys-rich region CR1 and modules 2–7 of CR2. Three types of disulfide bonded modules are indicated by
bars below the sequences, and residues not conforming to the CR1 pattern are shaded gray. The unfilled bars below parts of the Cys-rich
sequences indicate modules with two disulfide bonds (in a Cys 1-3 and 2-4 arrangement), the solid bars indicate modules that contain a
single disulfide bond and have a -finger motif, and the dashed bar indicates residues present in a disulfide-linked bend consisting of only
five residues. Disulfide bonds are shown in solid lines, except for those that do not conform to the CR1 pattern, which are indicated as dashed
lines. The number in parentheses shows where amino acids have been omitted. Boxed residues and secondary structure elements are as in
(A). Residues buried at protein-protein interfaces are indicated as follows: L, CR1 loop residues that are buried; P, residues to which the CR1
loop binds; D, other residues in the dimer interface.
(C) Human TGF, EGF, and heparin binding EGF. The numbers 1, 2, and 3 indicate ligand residues contacting L1, L2, or both L1 and L2,
respectively. The positions of the two sets of  strands in the ligand are indicated by black and gray arrows above the sequences. One of
these sets of  strands (black) forms a  sheet with the black  strand of the receptor (see A). Disulfide bond connections are shown as solid
lines. The apostrophes above and below the sequences indicate intervals of ten residues. This figure was prepared using ALSCRIPT.
The most striking feature of CR1 is a large ordered Structure of TGF
More than ten mitogenic peptides form a family of li-loop from module 5 that projects directly away from
the ligand binding site. The loop consists of residues gands that can bind to members of the EGFR family.
However, apart from residues Gly19, Gly40, and the242–259 and contains an antiparallel -ribbon (Figure
2). This loop is highly conserved within the EGFR family three conserved disulfide bonds that are needed to
maintain structure, only Arg42 is conserved throughoutand is not present in IGF-1R (Figure 3B) or other mem-
bers of the insulin receptor family. It is a major contribu- the family, and pairwise sequence identities between
the ligands are often less than 35%. Three-dimensionaltor to the receptor-receptor contacts in the back-to-
back dimer (Figures 1A and 1B). structures have been determined by NMR for EGF (Mon-
Crystal Structure of TGF:EGF Receptor Complex
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Figure 4. Stereo View of Ligand C Traces
Ligands were superimposed using the C
atoms of core residues (see text). The C
traces have been rotated 55 about a hori-
zontal axis relative to Figure 5 and are as
follows: TGF molecules C (red with yellow
disulfide bonds) and D (blue) from this study;
minimized average NMR structure of TGF
(orange) from PDB:2TGF (Harvey et al., 1991);
diphtheria toxin bound heparin binding EGF
(gray) from PDB:1XDT (Louie et al., 1997); and
crystallized human EGF molecule A (purple)
and molecule B (green) from PDB:1JL9 (Lu et
al., 2001). While the two TGFmolecules from
this study (C and D), EGF molecule A of 1JL9,
and hbEGF superimpose well from residue
14, the top half of the B loop adopts different
conformations in the NMR structure (2TGF)
and 1JL9:B (top of each panel). In the uncom-
plexed form, the N terminus of TGF is struc-
turally heterogeneous (bottom left of each
panel).
telione et al., 1987; Cooke et al., 1987; Kohda and Ina- The footprint of the ligand on the receptor covers most
of the large (second) sheet of each L domain, runninggaki, 1992; Barnham et al., 1998), TGF (Tappin et al.,
1989; Harvey et al., 1991; Moy et al., 1993), and heregulin from the top left corner to abut the loop in the fourth
rung of the solenoid (Figures 1 and 5). The involvement(Nagata et al., 1994; Jacobsen et al., 1996) and by X-ray
crystallography for heparin binding EGF (hbEGF) in com- of both the L1 and L2 domains in ligand binding is con-
sistent with the results of chicken-human EGF receptorplex with diphtheria toxin (Louie et al., 1997) and EGF
(Lu et al., 2001). These structures show that TGF and domain swapping experiments (Lax et al., 1989). The
buried surface area on each L domain is similar to thatits relatives are relatively flexible molecules built on a
small structurally conserved core (Figure 4). In particu- found in antibody-antigen interactions and suggests
that each L domain could possibly bind a ligand on itslar, the 14 N-terminal residues, the “B loop,” and the
extreme C terminus are often quite disordered. From a own. Indeed, this has been shown for the L2 domain,
where a proteolytic fragment was capable of bindingcomparison of the two molecules of EGF in the asym-
metric unit, Lu et al. (2001) found that the common struc- EGF (Kohda et al., 1993), and for the L1-CR1 fragment
of ErbB3, which bound heregulin (Singer et al., 2001).tural core comprised only residues 13–21 and 30–47
(equivalent to 15–22 and 31–48 in TGF; Figure 3C), In the contact with L1, the inner curved face of the
crescent-shaped TGF sits across the large sheet andwhich encompassed half of the large-ribbon and a small,
C-terminal -ribbon. The structure of TGF, seen here in extends to the N-terminal helix of L1 (Figure 5). More
than half the buried surface area of L1 comes from athe complex, shows substantially more order, with a third,
N-terminal  strand (residues 4–6) aligned with the large V-shaped loop (residues 8–18) that runs across the large
sheet, replacing the first strand of the corresponding-ribbon (residues 19–33) to form a three-stranded 
sheet and an ordered C terminus. The structure of TGF sheet in IGF-1R. In the center of this interface, TGF
makes contact with the receptor, primarily via mainin the 2:2 complex is triangular or crescent-shaped. The
two TGF molecules in the dimer superimpose well on chain atoms. One strand from the large  sheet of TGF
(residues 29–35) sits edge on to the receptor and alignseach other (rmsd 0.70 A˚ for 44 C atoms; Figure 4). They
are structurally similar to the human EGF molecule A with the latter part of the V-shaped loop (residues 15–17).
This enables the receptor to contribute part of the V as(rmsd 1.33 A˚ for 41 Catoms) in the EGF crystal structure
(Lu et al., 2001) and even more closely to hbEGF (0.66 A˚ a fourth parallel  strand to the first and larger of the
ligand’s two  sheets (Figure 5A). Asn12, which is con-for 34 C atoms) in its complex with diphtheria toxin
(Louie et al., 1997). served in all of the EGFR family except ErbB2, makes
a side chain to main chain contact with the peptide N
atom of Gly40 in TGF, and the O1 atom of Thr15 fromLigand-Receptor Interactions
In the complex, TGF interacts with the large  sheets L1 makes a hydrogen bond to Ala41 O of TGF (Figure
5B). This interface is also characterized by two hy-of both the L1 and L2 domains of one receptor molecule
(Figures 1 and 5). Relative to IGF-1R, the position of L2 drophobic contacts around Leu14 and Leu17 from L1
and hydrophilic and electrostatic interactions involvingcorresponds to a rotation by 105at the L2/CR1 module7
interface or 122–130, relative to L1 of IGF-1R. More His4 and the B loop residues Arg22, Gln26, Glu27, and
Lys29 of TGFwith the L1 domain residues Tyr45, Tyr89,than a third of the ligand’s accessible surface area is
buried by the L1 and L2 domains of the receptor (about Glu90, Tyr101, Arg125, and Asn128 (Figure 5). The loca-
tion of the N terminus of TGF near Tyr101 in the com-745 A˚2 by L1 and about 785 A˚2 by L2), and over 60% of
the ligand’s residues make contact with the receptor. plex is consistent with the chemical crosslinking data
Cell
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Figure 5. Structure of the Ligand:Receptor Binding Surfaces
(A) Ribbon representation showing the contacts between sEGFR501 (orange with gray side chains) and TGF (green) viewed from the left in
Figure 1A. Residue numbers for TGF are italicized. O and N atoms are shown in red and blue, respectively.
(B) As in (A) but rotated 180.
of Woltjer et al. (1992). It should be noted that the lack of the ligands (reviewed by Groenen et al., 1994) are
consistent with the structure of the complex and high-of conservation in ErbB2 of two key residues in this
interface (Arg for Thr/Ser at position 15 and Met for Asn light the critical importance of Arg42 and Leu48. Binding
to the receptor does restrict the choice of ligand sideat position 12) would prevent any of the EGF family of
ligands from binding to L1 due to steric hindrance and chain in some positions. Residue 24 (TGF) is always
aliphatic (Leu, Ile, or Val) and residue 31 is a small aminoa loss of a hydrogen bond.
The interface between L2 and TGF is formed mostly acid such as Ala, Ser, or Thr. Both are buried in the L1
interface. The conservation of Arg42 and Leu48 hadfrom the side chain atoms of both the ligand and recep-
tor. TGF sits on the flat face (i.e., the large  sheet) been observed, but conservation of an aromatic residue
at 15 and a hydrophobic residue at 17 are necessaryof L2, surrounded by three loops (residues 316–326,
352–363, and 405–412) that project out from the plane both for ligand binding and for holding Arg42 in the
correct orientation. The cluster of His residues in theof the sheet (Figures 5A and 5B). The contact between
the ligand and receptor is an alternating series of stripes middle of the L2 interface may play a part in release of
the ligand at low pH following endocytosis.of hydrophobic and hydrophilic interaction across the
interface. These are as follows: (1) Phe15 of TGF sits
against Phe357 of EGFR; (2) the strictly conserved Arg42 Receptor-Receptor Interactions
Unlike other growth factor receptor complexes, the li-of TGF is sandwiched between Phe15 and Phe17 of
the ligand, facilitating the correct orientation and envi- gand is not found at the dimer interface in the 2:2 com-
plex of TGF:sEGFR501. Thus, ligand-induced dimer-ronment to make a salt bridge with the strictly conserved
Asp355 of the receptor; (3) Phe17 and the lower part ization of sEGFR501 implies that binding of ligand
induces a conformational change in the receptor thatof Glu44 from TGF interact with Leu325, Leu348, and
Val350 from L2; (4) the next hydrophilic region contains promotes receptor-receptor interactions. The most no-
table feature of the back-to-back dimer is a long loopfour histidines, His18 and His45 of TGF and His346
and His409 of L2, as well as Tyr38 and Glu44 from TGF (residues 242–259) that is specific to the EGFR family
and is not found in the CR of IGF-1R (Figures 2 and 3B)and Gln384 and Gln408 from L2; and (5) there is a
hydrophobic pocket in L2 (Leu382, Gln408, His409, or other members of the insulin receptor family. From
each receptor, the loop projects out from the fifth mod-Phe412, Val417, Ile438) centered over Ala415, which
holds the highly conserved Leu48 of TGF (Leu47 in ule of CR1, across the other CR1 domain to a space
between L1, L2, and CR1 domains of the neighboringEGF), the ligand residue with the largest buried surface.
The C terminus of TGF is sandwiched between do- receptor (Figures 1A and 1B). Contact is made by resi-
dues 244–253 of the CR1 loop in, say, molecule A withmains L1 and L2, with the side chain of Leu49 contacting
both L domains. Leu49 may well define the final position- residues 229–239, 262–278, and 282–288 on the concave
face of the CR1 domain of molecule B (Figure 6). Theing of the L domains in the complex. Lys465 from L2 is
near the C terminus of TGF and may stabilize the termi- buried surface areas are 480 A˚2 and 330 A˚2, respectively.
At specific positions in the CR1 loop, there is remarkablenal carboxyl group. Lys465 has been chemically cross-
linked to residue 45 in a mutant form of mouse EGF sequence conservation across all ErbB family members.
Tyr246 is strictly conserved and is completely buried in(Summerfield et al., 1996). Some carbohydrate nearby
could possibly also affect ligand binding. the interface. The O atom of TyrA246 (receptor mole-
cule A) makes hydrogen bonds with the GlyB264 N andData from chemical crosslinking (Woltjer et al., 1992;
Summerfield et al., 1996) and site-directed mutagenesis CysB283 O atoms (receptor molecule B), and the phenyl
Crystal Structure of TGF:EGF Receptor Complex
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Figure 6. Stereo View of the Contacts be-
tween the CR1 Loop of EGFR Molecule A with
CR1 of EGFR Molecule B in the Back-to-Back
Dimer Interface
CR1 loop of EGFR molecule A is shown in
orange, and CR1 of EGFR molecule B is in
gray. Interchain hydrogen bonds are drawn
in black along with the hydrogen bond from
Asn247 of molecule A (not labeled), which
appears to stabilize the loop tip conforma-
tion. The single letter code and residue num-
ber is used for amino acid residues. The dimer
axis lies vertically at the left at H280.
ring sits against the C atoms of SerB262 and SerB282 complex, mutant receptors designed to probe the two
dimer interfaces were analyzed. Single amino acid sub-and the face of the following peptides (Figure 6). Residue
251 is strictly conserved as Tyr or Phe and in this inter- stitutions Glu21Ala, Arg470Leu, Asn473Asp, Ser474Glu,
and Ala477Asp were prepared to test the head-to-headface makes a hydrophobic contact via the benzene ring
with the PheB263, GlyB264, TyrB275, and ArgB285. The dimer. When transiently expressed in 293 cells, which
express low endogenous levels of EGFR (1  104 re-O of TyrA251 is exposed to solvent. Additional hy-
drophobic contacts are made by ProA248 to PheB230 ceptors/cell), or when stably expressed (Glu21Ala) in the
hemopoietic cell line BaF/3, which does not expressand AlaB265 and by MetA253 to ThrB278. There is also a
hydrogen bond from TyrA251 O to ArgB285 N (Figure 6). EGFR family members (Walker et al., 1998), these mu-
tants showed normal EGF binding, kinase activation,Other conserved residues of the CR1 loop, such as
Asn247 and Asn256, do not make contact with the other dimerization (Figure 7), and internalization (data not
shown). In contrast, mutants of the back-to-back dimer,half of the dimer, but hydrogen bond back onto the main
chain and appear to be important for maintaining the a CR1 loop deletion (residues 	242–259) from the full-
length receptor and sEGFR501 with multiple substitu-loop in the appropriate conformation. There are four
positions in the loop (residues 243, 248, 255, and 257) tions in the CR1 loop (Tyr246Asp, Asn247Ala, Thr249Asp,
Tyr251Glu, Gln252Ala, and Met253Asp), were defective.where proline is found in at least one member of the
human EGFR family with ErbB3 having as many as three The 	CR1-loop clones fail to show ligand-induced di-
merization and ligand-induced receptor kinase activa-prolines. These prolines would further stabilize the con-
formation of the loop. tion and exhibit only low-affinity binding (Figures 7A–
7C). Anti-phosphotyrosine Western blotting (Figure 7C)The loop not only touches the CR1 domain of its part-
ner, but also reaches across to contact the L1 and L2 demonstrates the absence of ligand-induced receptor
autophosphorylation in the 	CR1-loop clones. Further-domains of the other receptor molecule (burying a sur-
face area of 40 A˚2 on L1 and 5 A˚2 on L2). AsnB86 touches more, ligand-induced tyrosine phosphorylation of other
substrates and activation of MAPK (as determined byThrA249 and, with a slight rearrangement, could form a
hydrogen bond between the side chains. Neither residue immunoblotting with antibodies that recognize phos-
pho-MAPK, data not shown) are missing in the 	CR1-is conserved in other ErbB receptors, although polar
residues predominate at these positions. ThrA250, loop clones. Similarly, the sEGFR501 mutant with multi-
which is conserved in other ErbB receptors, sits near ple CR1 loop substitutions fails to show ligand-induced
IleB318 but the reason for the conservation is not appar- dimerization (Figure 7D) and exhibits 15-fold lower affin-
ent. Although these interactions are quite weak, it is ity binding for EGF on BIAcore analysis (500 nM versus
possible that the binding of the loop from one receptor 30 nM for sEGFR501).
may be affected by binding of ligand to the other, as
ligand binding may alter the relative positions of the L
Conclusiondomains.
Ligand-induced dimerization (or oligomerization) of re-Two other regions also participate in the back-to-back
ceptors is a common means of signal transduction, anddimer contact. One is near the two long loops, where
in all cases seen so far the ligand participates directlyAsp279 and His280 of receptor A make contact across
in the dimerization of receptors. For VEGF/Flt-1 (Wies-the dimer axis with the corresponding residues from
mann et al., 1997), nerve growth factor (NGF)/TrkA re-receptor B (Figures 1A and 1B). A second region of
ceptor (Wiesmann et al., 1999), bone morphogenic pro-contact is near the N-terminal end of the CR1 domain
tein (BMP)/BMP receptor (Kirsch et al., 2000), interferonin Cys-rich module 2, where residues 193–195 and 204–
 (IFN)/IFN receptor (Thiel et al., 2000), and tumor205 from molecule A contact 193–194 and 204–205 from
necrosis factor (TNF)/TNF receptor (Banner et al., 1993),molecule B, burying about 225 A˚2.
the ligand is a dimer or trimer before forming the 2:2
complex or 3:3 complex and, in the structures deter-Functional Characterization of Mutant EGFRs
mined, the receptors do not contact each other. In theIn order to establish the biological relevance of the two
dimers identified in crystals of the TGF:sEGFR501 2:2 complex of the fibroblast growth factor (FGF)/FGF
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Figure 7. Functional Characterization of EGFR Mutants Expressed in BaF/3 Cells
(A) Ligand binding by wild-type and mutant EGFRs expressed in BaF/3 cells. Scatchard plots of 125I-EGF binding to clones expressing the wt,
E21A, or 	CR1 EGFR were analyzed using the Radlig program to yield estimates of receptor affinity. The three cell lines expressed comparable
receptor numbers as assessed by M2 or 528 antibody binding and FACS analysis. Shown are the plots for cold ligand titration assay; identical
results were obtained titrating the radiolabeled EGF.
(B) EGF-dependent tyrosine kinase activation. This was determined in total cell lysates by sequential immunoblotting with anti-phosphotyrosine
(top) or anti-EGFR (bottom) antibodies. The anti-EGFR antibodies have slightly lower affinity for the hyperphosphorylated form of the EGFR.
The results are representative of multiple experiments on at least four independently derived clones for each mutant.
(C) Ligand-induced EGFR dimerization. Crosslinking of the EGFR via the extracellular portion was performed using BS3 at 37C to maximize
dimer yield. Samples were analyzed by SDS-PAGE on 3%–8% gradient gels and immunoblotting with anti-EGFR antibodies. These data are
representative of at least four separate experiments.
(D) Ligand-induced sEGFR501 dimerization. Crosslinking of wild-type and CR1 loop mutant (Tyr246Asp, Asn247Ala, Thr249Asp, Tyr251Glu,
Gln252Ala, and Met253Asp) was carried out as described previously (Elleman et al., 2001).
receptor, the ligands do not contact each other but are two domains. Compared to IGF-1R, there is a substantial
rearrangement of L domains in EGFR (Figure 2), althoughdimerized by heparin (Plotnikov et al., 2000; Schles-
singer et al., 2000; Pellegrini et al., 2000). The FGF recep- a conformational change of such a magnitude would
not be necessary. A smaller change in L domain posi-tors do contact each other and the two FGF ligands lie
at the dimer interface with a heparin molecule sitting tions upon ligand binding, possibly with hinge motions
seen at the CR1 module 5/6, 6/7, and 7/L2 interfacesbetween two FGFs. In the 2:2 complex of granulocyte
colony-stimulating factor (GCSF)/GCSF receptor (Ari- (relative to IGF-1R), could enable EGFR extracellular
domains to form dimers.tomi et al., 1999), each ligand binds both receptors but
there are no contacts between the two ligands or the Clearly, the structure presented here contributes only
part of the information required to improve our under-two receptor fragments. Finally, in the growth hormone,
erythropoietin, and prolactin/receptor complexes, there standing of EGF receptor signaling at the cell surface.
Truncated forms of the receptor, such as delta 2-7 oris only one ligand molecule in the 1:2 complex, and the
two receptor molecules make contact with ligand and with the extracellular region deleted, are constitutively
active, indicating that determinants also exist in thewith each other (de Vos et al., 1992).
The back-to-back TGF:EGFR complex described transmembrane region and/or the intracellular domain
that facilitate receptor association and activation. Re-here and the EGF:EGFR complex reported by Ogiso et
al. (2002 [this issue of Cell]) represent new and surprising cently unligated EGFR dimers have been detected on
cell surfaces (Moriki et al., 2001). Ligand binding to theseways in which receptors and protein ligands interact.
EGFR ligands bind at a site remote from the dimer inter- preformed dimers may induce a reorientation of the ex-
tracellular domains with a consequential reorientationface to promote and/or stabilize receptor dimerization.
A precedent for this has been seen in the rat metabo- (and activation) of the kinase domains.
trophic glutamate receptor where the small ligand, gluta-
Experimental Proceduresmate, binds between two domains of the receptor mono-
mer, causing them to go from an “open” to a “closed”
Protein Preparation of sEGFR501
form (Kunishima et al., 2000). Such a mechanism could The derivation of stably transfected Lec8 cells expressing
also occur in the EGFR family where the ligand binds sEGFR501 and the subsequent purification and characterization of
the secreted ectodomain has been described in detail (Elleman etboth L1 and L2, fixing the relative orientations of the
Crystal Structure of TGF:EGF Receptor Complex
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al., 2001). Purified sEGFR501 was shown by isoelectric focusing (and a small portion of 5 noncoding sequence, base pair 131–261),
followed by the FLAG coding sequences with Hind III and Xho I ongels to be unstable on storage, the majority of isoforms being trans-
formed into products with less acidic isoelectric points. This change its 5 and 3 ends, respectively, cloned into a mammalian expression
vector pcDNA3 (Invitrogen). This yielded the wild-type N-terminalis accompanied by a small mobility increase (estimated at 1–2 kDa)
on SDS polyacrylamide gels. Sequence analysis showed that the tagged EGF receptor construct, M2-EGFR. PCR products con-
taining point mutations and CR1-loop deletion were cloned usingnew product had no N-terminal degradation, suggesting partial or
complete loss of the acidic residue-rich C-terminal tag and enteroki- the wild-type M2-EGFR as a template. The point mutation constructs
are E21A, R470L, N473D, S474E, and A477D. The CR1-loop deletionnase cleavage site. Prolonged storage led to the majority of protein
converting to the least acidic isoform of pI 6.6. The conversion of construct contains a replacement of nucleotides 988–1035 by GCC,
resulting in CR1-loop residues 244–259 being replaced by a singlea fresh preparation of sEGFR501 to a stable, less acidic isoform was
more reproducible and rapid if it was subject to limited proteolysis at alanine residue. The sEGFR501 CR1 loop mutant (Tyr246Asp,
Asn247Ala, Thr249Asp, Tyr251Glu, Gln252Ala, and Met253Asp) wasambient temperature in Tris-buffered saline (pH 8) for180 min with
endoproteinase Asp-N (Boehringer-Mannheim) at an enzyme:pro- generated by oligonucleotide-directed in vitro mutagenesis using
the USB-T7 Gen kit, transiently expressed, purified, and character-tein ratio of 1:1000 (w/w). The least-acidic isoform of apparent pI
6.2 was isolated from the other components by anion exchange ized as described previously (Elleman et al., 2001).
chromatography. The digest was bound to three Uno Q2 columns
(BioRad) connected in series to a BioLogic HR liquid chromatogra- Functional Analysis of EGFR Mutants
NIH3T3 and/or 293 cells (American Type Culture Collection) werephy instrument in 20 mM ethanolamine/50 mM taurine (pH 8.0)
buffer, and the least acidic form was the first product obtained by grown and transfected as described previously (Walker et al., 1998).
Two days after transfection, cells were washed with serum-freeisocratic elution in the same buffer containing 15 mM lithium acetate.
The purified protein was incubated with endoglycosidase F medium, starved for 2 hr, and treated with or without EGF (100 ng/
ml) for 10 min. Whole-cell lysates were prepared and fractionated(PNGase-free; Boehringer Mannheim) at a ratio of 10–20 Units/mg
protein, followed by rechromatography over Superdex 200 to re- by SDS-gel electrophoresis using 4%–20% polyacrylamide gels and
Western blots developed using monoclonal antibodies M2 (anti-move enzyme and low-molecular-weight cleavage products.
FLAG, Sigma, Brizzard et al., 1994) or 4G10 (anti-phosphotyrosine,
Upstate Biotechnology) as described (Walker et al., 1998).Crystallization and Data Collection
sEGFR501 obtained from the above procedures appeared nearly
Characterization of Wild-Type and Mutant EGFR Stablyhomogeneous on SDS and IEF gels and was used in crystallization
Expressed in BaF/3 Cells.trials alone and in combination with several ligands. The best-dif-
Expression vectors containing the mutant EGFR constructs werefracting crystals were obtained from mixtures containing a 5-fold
transfected into the IL-3-dependent murine hemopoietic lineagemolar quantity of human TGF (GroPep receptor grade) compared
BaF/3, selected, and analyzed as described previously (Walker etto sEGFR501. Crystals of sEGFR501 in complex with TGF were
al., 1998). Receptor dimerization was mentioned by crosslinkinggrown in 7% PEG 3350, 20% Trehalose, 10 mM CdCl2, and 100 mM
with the water-soluble homobifunctional crosslinker BS3 (Pierce) atHEPES (pH 7.5) mother liquor and belonged to the space group P21
a final concentration of 1.2 mM. Scatchard plots and estimates(a  51.59, b  198.71, c  78.90 A˚,   102.03). These crystals
of affinities and receptor numbers were obtained using the Radligwere cryo-cooled to 170C in the same mother liquor. Data were
program (Kell for Windows, BioSoft). Ligand-induced receptor ki-recorded on a Rigaku RAXIS VI area detector using a Siemens
nase activation was analyzed by Western blotting the cell lysatesM18XHF X-ray generator with Yale/MSC mirrors or a Rigaku RU300
with the anti-phosphotyrosine monoclonal antibody 4G10 (Upstategenerator and AXCO capillary optics. Crystals were also derivatized
Biotechnology).by soaking in mother liquors containing 1–10 mM heavy atom com-
pounds, and diffraction data were collected as before and statistics
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